Compositions and methods for detecting pancreatic cancer

A method of diagnosing and treating a subject having intraductal papillary mucinous neoplasm (IPMN), the method comprising:

• a) detecting in a sample from a subject an increased level relative to a healthy subject of two or more markers selected from the group consisting of OPN, MIA, CEACAM-1, MIC-1, SPON1, HSP27, POSTN, and LGALS3BP, and
• b) determining the subject has intraductal papillary mucinous neoplasm (IPMN) based on the increased level of markers;
• c) treating the subject for intraductal papillary mucinous neoplasm (IPMN).

A method of diagnosing and treating a subject having pancreatic ductal adenocarcinoma (PDAC), the method comprising:

• a) detecting in a sample from a subject an increased level relative to a healthy subject of two or more markers selected from the group consisting of OPN, MIA, CEACAM-1, MIC-1, SPON1, HSP27, POSTN, and LGALS3BP, and
• b) determining the subject has pancreatic ductal adenocarcinoma (PDAC) based on the increased level of markers;
• c) treating the subject for pancreatic ductal adenocarcinoma (PDAC).

A method of detecting pancreatic cancer in a subject, the method comprising:

• (a) measuring in a sample from the subject a level of a polynucleotide or polypeptide of at least one marker selected from the group consisting of:
• OPN, MIA, CEACAM-1, MIC-1, SPON1, HSP27, POSTN, and LGALS3BP relative to a reference,
• wherein an increased level of said polynucleotide or polypeptide relative to a reference indicates presence of pancreatic cancer in the subject.